MC Sciences is a pre-clinical company developing the next generation therapeutics targeting mast cells in immunology, inflammation and dermatology, and has this year been a finalist at the BIO Start-Up Stadium in Boston. Chronically activated mast cells are key drivers in several diseases affecting large patient populations and the selective and complete inhibition of activated mast cells remains a high need. Key diseases indications include chronic urticaria, contact dermatitis, IBD / IBS, rare disease systemic mastocytosis, pulmonary fibrosis, NASH / liver fibrosis, MCAS, allergies, and chronic disorders such as chronic lyme and long covid. Key asset of MC Sciences is the discovery of a novel receptor that controls the entire mast cell activity and targeted small molecules that selectively deactivate only the dysfunctional mast cells (without immune-related side effects). In consequence, the MC Sciences novel small molecules combine and increase the therapeutic efficacy of other mast cell targeting drugs (for example KIT, MRGPRX2, FceRI, IL-33, BTK) together with an excellent safety profile. Key advantage is the high probability for clinical success: MC Sciences novel biology discovery is based on clinical observation in humans and extensive human proof-of-concept studies. The attractive market position as Next Generation Therapeutics is based on: a. High therapeutic efficacy and disease-modifying b. Excellent safety profile d. Novel biology being first-and-best-in-class c. Lead program MCS11XX with accelerated path to clinics and high probability for success f. Multi-product in-a-pipeline for several disease indications MC Sciences is currently progressing it’s lead program towards best candidates for an accelerated path to clinics. MC Sciences is driven by a world-class team combining leading mast cell scientists, excellent drug development capabilities, execution excellence and a global leading medical mast cell disease network.